# Phase 2 Multiple Myeloma trials recruiting: 129 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 129 trials in phase 2 for Multiple Myeloma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Multiple Myeloma trials: 129 rows for $6.45, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/multiple-myeloma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 129
- Recruiting or not yet: 129
- Read on: November 19, 2026

## Trials

The 25 newest of 129, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931391 | SKCD in Early Relapsed/Refractory Multiple Myeloma | Beijing Chao Yang Hospital | Phase 2 | Recruiting | Multiple Myeloma (MM) | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931391) |
| October 29, 2026 | NCT07903636 | QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma (MM) | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903636) |
| October 28, 2026 | NCT07901868 | Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | PETHEMA Foundation | Phase 2 | Not yet recruiting | Multiple Myeloma Refractory, Multiple Myeloma in Relapse | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901868) |
| October 26, 2026 | NCT07895017 | Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias | University of Virginia | Phase 2 | Not yet recruiting | Thrombocytopenia | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07895017) |
| September 25, 2026 | NCT07842198 | Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy | Zealand University Hospital | Phase 2 | Not yet recruiting | Large B-Cell Lymphoma (LBCL), Multiple Myeloma (MM), Gut Microbiota | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842198) |
| September 21, 2026 | NCT07830485 | CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07830485) |
| September 18, 2026 | NCT07828522 | F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma (MM), Transplant-eligible Patients | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828522) |
| September 17, 2026 | NCT07825064 | Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously... | Hoffmann-La Roche | Phase 2 | Recruiting | Multiple Myeloma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07825064) |
| September 10, 2026 | NCT07811986 | HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma (MM) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811986) |
| August 27, 2026 | NCT07789522 | Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma (MM) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07789522) |
| August 18, 2026 | NCT07771361 | BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma | Luminary Therapeutics | Phase 2 | Not yet recruiting | Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Non-Hodgkin... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07771361) |
| August 14, 2026 | NCT07764861 | A Open-Label Phase in Participants With Multiple Myeloma | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Not yet recruiting | Multiple Myeloma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764861) |
| August 11, 2026 | NCT07757412 | Teclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple... | Odense University Hospital | Phase 2 | Not yet recruiting | Multiple Myeloma Progression | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07757412) |
| August 6, 2026 | NCT07748689 | Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple... | Polish Myeloma Consortium | Phase 2 | Not yet recruiting | Relapsed / Refractory Multiple Myeloma | 228 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748689) |
| July 10, 2026 | NCT07695740 | Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma | Excyte Biopharma Ltd | Phase 2 | Not yet recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07695740) |
| July 8, 2026 | NCT07689058 | CAR-T in Relapsed/Refractory Multiple Myeloma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Multiple Myeloma Refractory, Multiple Myeloma in Relapse | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689058) |
| June 18, 2026 | NCT07657312 | Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory... | Sponsor not shown (see the record) | Phase 2 | Recruiting | Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657312) |
| June 15, 2026 | NCT07648459 | CM336-SOC for Dynamically High-Risk Multiple Myeloma Study | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Not yet recruiting | Multiple Myeloma | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07648459) |
| June 10, 2026 | NCT07638683 | A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple... | Shanghai Zhongshan Hospital | Phase 2 | Recruiting | Multiple Myeloma, AL Amyloidosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638683) |
| June 10, 2026 | NCT07637578 | A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma | SCRI Development Innovations, LLC | Phase 2 | Recruiting | Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637578) |
| May 29, 2026 | NCT07614360 | Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With... | GlaxoSmithKline | Phase 2 | Not yet recruiting | Multiple Myeloma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07614360) |
| May 15, 2026 | NCT07589634 | A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants... | Janssen Research & Development, LLC | Phase 2 | Recruiting | Multiple Myeloma | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589634) |
| May 14, 2026 | NCT07585760 | CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07585760) |
| May 5, 2026 | NCT07567014 | Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS | NYU Langone Health | Phase 2 | Not yet recruiting | Multiple Myeloma, Large B-cell Lymphoma (LBCL) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07567014) |
| April 3, 2026 | NCT07509086 | IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia | The First Hospital of Jilin University | Phase 2 | Recruiting | Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07509086) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Institute of Hematology & Blood Diseases Hospital, China | 15 |
| Memorial Sloan Kettering Cancer Center | 5 |
| Massachusetts General Hospital | 4 |
| Mayo Clinic | 4 |
| M.D. Anderson Cancer Center | 4 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 4 |
| National Cancer Institute (NCI) | 3 |
| SCRI Development Innovations, LLC | 3 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 2 |
| Emory University | 2 |
| Medical College of Wisconsin | 2 |
| University of Utah | 2 |
| The First Affiliated Hospital of Xiamen University | 2 |
| Xuzhou Medical University | 2 |
| University of Miami | 2 |
| Canadian Cancer Trials Group | 1 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 1 |
| Zealand University Hospital | 1 |
| Seoul National University Hospital | 1 |
| NYU Langone Health | 1 |
| PETHEMA Foundation | 1 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 1 |
| Masonic Cancer Center, University of Minnesota | 1 |
| Canadian Myeloma Research Group | 1 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 71 |
| China | 26 |
| Spain | 9 |
| France | 6 |
| Canada | 4 |
| Denmark | 4 |
| South Korea | 4 |
| Germany | 4 |
| United Kingdom | 4 |
| Netherlands | 4 |
| Australia | 3 |
| Japan | 3 |
| Israel | 3 |
| Norway | 3 |
| Greece | 3 |
| Belgium | 3 |
| Italy | 3 |
| Poland | 3 |
| Estonia | 2 |
| Puerto Rico | 2 |
| Sweden | 2 |
| Switzerland | 1 |
| Finland | 1 |
| Ireland | 1 |
| Brazil | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Seafood wholesalers in the United States](https://specstream.ai/data/businesses/seafood-wholesalers/united-states)
- [Wholesale grocers in the United States](https://specstream.ai/data/businesses/wholesale-grocers/united-states)
- [Breweries in the United States](https://specstream.ai/data/businesses/breweries/united-states)
- [Egyptian restaurants in the United States](https://specstream.ai/data/businesses/egyptian-restaurants/united-states)
- [HR services firms in the United States](https://specstream.ai/data/businesses/hr-services-firms/united-states)
- [Obstetrics and gynecology practices in the United States](https://specstream.ai/data/businesses/obstetrics-and-gynecology-practices/united-states)
